Iretig

Mirabegron, the active ingredient in Iretig, is a β3‑adrenergic receptor agonist presented as an oral formulation for adult use. It is indicated for the management of overactive bladder symptoms such as urgency, frequency, and urge urinary incontinence.

GNH USA supplies Iretig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is used to treat conditions within the overactive bladder disease family by relaxing the detrusor muscle and increasing bladder capacity.

Overactive bladder: reduces the number of urgency episodes and improves overall bladder control. Urinary urgency: helps patients regain control over sudden urges to void. Urinary frequency: decreases daytime voiding frequency. Urge urinary incontinence: lowers the frequency of involuntary leakage episodes.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache - Elevated blood pressure - Nasopharyngitis - Dry mouth - Constipation - Urinary retention (mild)

Serious or Rare Side Effects: - Acute urinary retention requiring catheterisation - Severe hypertension or hypertensive crisis - Anaphylactic or severe allergic reactions - Cardiac arrhythmias - Bladder pain or cystitis

Before initiating therapy, clinicians should evaluate relevant patient factors and monitor for potential risks.

Assess blood pressure: ensure baseline values are within acceptable range. Monitor for urinary retention: watch for signs of incomplete bladder emptying. Use caution in uncontrolled hypertension: avoid dose escalation. Evaluate renal function: adjust therapy if severe impairment is present. Review concomitant adrenergic agents: consider additive effects. Store at below 25°C: keep in the original pack, protect from moisture.

Mirabegron may interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) may increase mirabegron exposure. - Monoamine oxidase (MAO) inhibitors can raise the risk of hypertensive events.

Moderate Interactions (Monitor Closely): - Diuretics may amplify blood pressure changes. - Anticholinergic agents could diminish therapeutic benefit. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may contribute to elevated blood pressure.